These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 29200288)

  • 1. Novel Molecules To Treat Chronic Central Nervous System Toxoplasmosis.
    Kortagere S
    J Med Chem; 2017 Dec; 60(24):9974-9975. PubMed ID: 29200288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.
    Rutaganira FU; Barks J; Dhason MS; Wang Q; Lopez MS; Long S; Radke JB; Jones NG; Maddirala AR; Janetka JW; El Bakkouri M; Hui R; Shokat KM; Sibley LD
    J Med Chem; 2017 Dec; 60(24):9976-9989. PubMed ID: 28933846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.
    Doggett JS; Ojo KK; Fan E; Maly DJ; Van Voorhis WC
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3547-9. PubMed ID: 24687502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.
    Hulverson MA; Bruzual I; McConnell EV; Huang W; Vidadala RSR; Choi R; Arnold SLM; Whitman GR; McCloskey MC; Barrett LK; Rivas KL; Scheele S; DeRocher AE; Parsons M; Ojo KK; Maly DJ; Fan E; Van Voorhis WC; Doggett JS
    J Infect Dis; 2019 Apr; 219(9):1464-1473. PubMed ID: 30423128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture.
    Kuhlenschmidt TB; Rutaganira FU; Long S; Tang K; Shokat KM; Kuhlenschmidt MS; Sibley LD
    Antimicrob Agents Chemother; 2016 Jan; 60(1):570-9. PubMed ID: 26552986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis.
    Janetka JW; Hopper AT; Yang Z; Barks J; Dhason MS; Wang Q; Sibley LD
    J Med Chem; 2020 Jun; 63(11):6144-6163. PubMed ID: 32420739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis.
    Moine E; Moiré N; Dimier-Poisson I; Brunet K; Couet W; Colas C; Van Langendonck N; Enguehard-Gueiffier C; Gueiffier A; Héraut B; Denevault-Sabourin C; Debierre-Grockiego F
    Int J Parasitol; 2018 Jun; 48(7):561-568. PubMed ID: 29524527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.
    Larson ET; Ojo KK; Murphy RC; Johnson SM; Zhang Z; Kim JE; Leibly DJ; Fox AM; Reid MC; Dale EJ; Perera BG; Kim J; Hewitt SN; Hol WG; Verlinde CL; Fan E; Van Voorhis WC; Maly DJ; Merritt EA
    J Med Chem; 2012 Mar; 55(6):2803-10. PubMed ID: 22369268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
    Lapinskas PJ; Ben-Harari RR
    Postgrad Med; 2019 Nov; 131(8):589-596. PubMed ID: 31399001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.
    Castellanos-Gonzalez A; White AC; Ojo KK; Vidadala RS; Zhang Z; Reid MC; Fox AM; Keyloun KR; Rivas K; Irani A; Dann SM; Fan E; Maly DJ; Van Voorhis WC
    J Infect Dis; 2013 Oct; 208(8):1342-8. PubMed ID: 23878324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
    Moine E; Dimier-Poisson I; Enguehard-Gueiffier C; Logé C; Pénichon M; Moiré N; Delehouzé C; Foll-Josselin B; Ruchaud S; Bach S; Gueiffier A; Debierre-Grockiego F; Denevault-Sabourin C
    Eur J Med Chem; 2015 Nov; 105():80-105. PubMed ID: 26479029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potential Toxoplasma gondii CDPK1 inhibitors with new scaffolds based on the combination of QSAR and scaffold-hopping method with in vitro validation.
    Zhang P; Jia L; Tian Y; Xi L; Duan R; Chen X; Xiao J; Yao X; Lan J; Li S
    Chem Biol Drug Des; 2020 May; 95(5):476-484. PubMed ID: 31436911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability.
    Zwicker JD; Diaz NA; Guerra AJ; Kirchhoff PD; Wen B; Sun D; Carruthers VB; Larsen SD
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1972-1980. PubMed ID: 29650289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum.
    Winzer P; Müller J; Aguado-Martínez A; Rahman M; Balmer V; Manser V; Ortega-Mora LM; Ojo KK; Fan E; Maly DJ; Van Voorhis WC; Hemphill A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6361-74. PubMed ID: 26248379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly(lactide-co-glycolide) microspheres induces long-term protective immunity in mice.
    Zhang NZ; Xu Y; Wang M; Chen J; Huang SY; Gao Q; Zhu XQ
    BMC Infect Dis; 2016 Apr; 16():168. PubMed ID: 27090890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites.
    Murata Y; Sugi T; Weiss LM; Kato K
    PLoS One; 2017; 12(6):e0178203. PubMed ID: 28609444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
    Shubar HM; Lachenmaier S; Heimesaat MM; Lohman U; Mauludin R; Mueller RH; Fitzner R; Borner K; Liesenfeld O
    J Drug Target; 2011 Feb; 19(2):114-24. PubMed ID: 20367080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying the Target of an Antiparasitic Compound in
    Herneisen AL; Sidik SM; Markus BM; Drewry DH; Zuercher WJ; Lourido S
    ACS Chem Biol; 2020 Jul; 15(7):1801-1807. PubMed ID: 32597628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
    Jost C; Reiter-Owona I; Liesenfeld O
    Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.